Pharmaceutical Technology32 分钟
Calquence by AstraZeneca for Graft Versus Host Disease (GVHD): Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).
Pharmaceutical Technology35 分钟
NEXI-001 by NexImmune for Myelodysplastic Syndrome: Likelihood of Approval
NEXI-001 is under clinical development by NexImmune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase ...